Stock listing

Stuttgart:4RM0 Catheter Precision, Inc. Aktie

German listing (Stuttgart) of Catheter Precision, Inc. · home listing NYSE American:VTAK

Follow Catheter Precision, Inc. into a list and get an email when it puts out news.

Catheter Precision, Inc. logo
Ticker
Stuttgart:4RM0
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
Stuttgart
Currency
EUR

What changed lately

Latest news

All Catheter Precision, Inc. news

Catheter Precision, Inc. on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
40 in the last 12 months · 66 in all · newest Sep 17, 2026 · oldest 2025
Decks
11 decks · latest Mar 12, 2025

Where Catheter Precision, Inc. is listed

ListingExchangeCountryCurrency
NYSE American:VTAK · Home listingNYSE AmericanUnited StatesUSD
BOATS:VTAKBOATSUnited StatesUSD
Frankfurt:4RMFrankfurtGermanyEUR
gettex:4RMgettexGermanyEUR
Munich:4RMMunichGermanyEUR
Stuttgart:4RM0 · This pageStuttgartGermanyEUR

Valuation

Statements: 4 quarters to Jun 30, 2026

Enterprise value
No market cap
P/E
No market cap
EV/sales
No market cap
EV/EBITDA
No market cap
Price/book
No market cap
Gross margin
47.7%
Operating margin
−635.0%
Net margin
−661.4%
Debt to equity
0.2×
Beta vs S&P 500
0.97

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
2.00 USD · Analysts' mean
EPS, year to Dec 2024
-8.70 · 1 analyst
Revenue, year to Dec 2024
3.19M · 1 analyst

Team and board

OfficerRole
David JenkinsChief Executive Officer
Phil AndersonChief Financial Officer

Events

QuarterResultsShare move
Quarter to Sep 30, 2026Nov 12, 2026
Q2 2026Aug 14, 2026−20.7%
Q1 2026May 18, 2026+7.9%
Q3 2025Nov 13, 2025−16.0%
Q2 2025Aug 11, 2025−10.5%
Q1 2025May 5, 2025 · After close−3.6%
Q4 2024Mar 27, 2025 · After close−7.9%
Q3 2024Nov 14, 2024 · Before open+4.2%
Q2 2024Aug 14, 2024 · Before open+1.9%
Q1 2024May 6, 2024 · After close+1.8%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 29, 2024 · After close+2.0%
Q3 2023Dec 21, 2023 · After close+5.0%
Q2 2023Aug 14, 2023−1.6%
Q1 2023Jun 2, 2023 · After close+1.9%
Q4 2022Mar 14, 2023−0.6%
Q3 2022Nov 16, 2022−9.2%
Q2 2022Aug 15, 2022
Q1 2022May 16, 2022
Q4 2021Mar 23, 2022
Q3 2021Nov 15, 2021

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2025)Investor deck25 slidesMar 12, 2025
IPO Roadshow (June 2024)IPO roadshow101 slidesJun 17, 2024
Ra Medical Systems — IPO Roadshow (January 2022)IPO roadshow21 slidesJan 28, 2022
Ra Medical Systems — Investor Presentation (August 2021)Investor deck19 slidesAug 24, 2021
Ra Medical Systems — Investor Presentation (March 2021)Investor deck20 slidesMar 8, 2021
Ra Medical Systems — Investor Presentation (January 2021)Investor deck25 slidesJan 5, 2021
Ra Medical Systems — Investor Presentation (September 2020)Investor deck25 slidesSep 14, 2020
Ra Medical Systems — IPO Roadshow (July 2020)IPO roadshow26 slidesJul 27, 2020
Ra Medical Systems — IPO Roadshow (May 2020)IPO roadshow26 slidesMay 15, 2020
Ra Medical Systems — Investor Presentation (December 2019)Investor deck25 slidesDec 11, 2019
All 11 decks
DeckKindSlidesDate
Ra Medical Systems — Investor Presentation (November 2018)Investor deck24 slidesNov 13, 2018

Open Decks

Financings

RaiseDate
Strategic investment of not specified
Announced: up to US$36.5M
Use of proceeds: Advance key growth initiatives, scale multiple business opportunities and expand market presence and execution capabilities
Feb 12, 2026
Private placement of series B Preferred Stock and warrants
Closed: US$1.5M raised · ½ warrant at US$0.5 for 66 months · Ladenburg Thalmann & Co. Inc.
Dealers: Ladenburg Thalmann & Co. Inc. (lead)
May 12, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue819.0K420.0K442.0K14.0K22.0K4.41M7.20M6.26M5.87M5.98M
Cost of revenue63.0K42.0K30.0K161.0K1.56M5.48M8.85M4.21M4.17M3.14M
Gross profit756.0K378.0K412.0K-147.0K-1.54M-1.08M-1.65M2.05M1.71M2.84M
Research and development862.0K272.0K475.0K6.39M12.3M9.01M4.53M2.78M4.52M1.72M
Selling, general and administrative12.1M11.3M17.1M2.23M15.5M26.0M51.5M30.4M
Operating income-12.2M-11.2M-78.1M-27.0M-29.3M-36.1M-57.7M-31.2M-17.8M-4.20M
Depreciation and amortization2.12M2.11M2.08M421.0K1.56M2.37M1.75M624.0K218.0K95.0K
EBITDA-10.1M-9.13M-76.0M-26.5M-27.7M-33.7M-56.0M-30.5M-17.5M-4.10M
Interest expense281.0K91.0K03.08M10.0K108.0K250.0K14.0K4.00K3.00K
Income before tax-19.5M-13.5M-70.6M-26.9M-27.3M-36.0M-56.9M-30.8M-17.8M-4.20M
Income tax-1.81M3.14M60.6M3.00K4.00K7.00K15.0K10.0K1.00K1.00K
Net income-17.2M-16.6M-70.6M-26.9M-25.1M-36.0M-57.0M-30.8M-17.8M-4.20M
Earnings per share, basic-15.90-96.89-2,440.16-4,936.60

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents88.0K2.87M3.56M15.9M15.0M23.9M14.6M64.3M8.24M3.92M
Short-term investments016.0M
Receivables155.0K70.0K137.0K75.6K21.0K24.0K786.0K1.32M517.0K393.0K
Inventory86.0K33.0K44.0K52.4K986.0K877.0K2.78M2.10M1.20M870.0K
Current assets390.0K3.29M4.16M16.8M17.1M27.6M36.0M69.2M10.0M5.31M
Property, plant and equipment3.92M5.01M
Total assets15.9M27.8M30.7M16.8M21.0M33.4M44.1M74.0M11.3M5.84M
Accounts payable1.49M230.0K464.0K92.0K988.0K471.0K1.53M1.13M426.0K473.0K
Current liabilities3.91M2.08M2.47M7.58M5.39M7.76M6.81M5.95M2.63M2.71M
Long-term debt3.08M1.50M1.58M265.0K
Total debt3.85M1.79M372.0K124.2K2.26M4.88M3.50M850.0K63.0K107.0K
Total liabilities9.21M16.0M9.54M7.58M7.37M12.3M10.9M7.33M18.9M6.22M
Shareholders' equity7.05M11.8M21.2M9.26M13.7M21.1M33.1M66.7M-7.62M-380.0K
Shares outstanding1.08M171.8K28.9K5.44K53217955535353

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-8.30M-9.27M-20.6M-22.6M-27.6M-28.3M-33.2M-18.5M-5.52M-1.89M
Capital spending-17.0K-67.0K-76.0K-17.0K-265.0K-67.0K-268.0K-582.0K-547.0K-210.0K
Free cash flow-8.31M-9.34M-20.7M-22.6M-27.9M-28.4M-33.4M-19.1M-6.07M-2.10M
Cash from investing167.0K-67.0K-61.0K21.0K3.80M15.9M-16.0M-582.0K-547.0K-210.0K
Cash from financing5.34M8.65M8.39M23.4M15.0M21.7M-526.0K75.2M10.4M5.37M
Dividends paid-5.16M-907.2K
Change in cash-2.79M-692.0K-12.3M814.0K-8.86M9.32M-49.7M56.1M4.32M3.28M

Open Financials

Cap table

Built by 6ix from Catheter Precision, Inc.’s releases · as of Feb 12, 2026

Common shares
1,897,204
Fully diluted
1,897,954

Fully diluted

LineSharesAs of
Common shares1,897,204
Warrants750May 12, 2025

Warrants and options

Lot
Warrants · US$0.50 · expire about Nov 2030

Share count over time

CountShares
Nov 22, 20261,897,204

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Hrt Financial LP202K1.4%US$30,000NewNov 13, 2026
Jane Street189K1.3%US$28,314NewNov 12, 2026
Citadel153K1.1%US$22,976NewNov 16, 2026
Goldman Sachs55,6300.39%US$8,345NewNov 16, 2026
Two Sigma22,1890.15%US$3,328NewNov 16, 2026
Osaic Holdings, Inc.9,5400.07%US$1,335+1,000Nov 12, 2026
Tower Research Capital LLC (TRC)4,7890.03%US$718−4,663Nov 16, 2026
Allworth Financial LP300<0.01%US$45No changeNov 17, 2026
Fidelity21<0.01%US$3NewNov 10, 2026
Purpose Unlimited Inc.13<0.01%US$2No changeNov 12, 2026
All 14 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Harbour Investments, Inc.8<0.01%US$1No changeNov 9, 2026
SBI Securities Co., Ltd.5<0.01%US$1No changeOct 21, 2026
Barclays5<0.01%US$1NewNov 6, 2026
Citigroup Inc1<0.01%−21Nov 4, 2026

Funds

HolderSharesOf the companyValueChangeAs of
Fidelity Extended Market Index Fund41,1940.29%US$36,251+34,591May 31, 2026
Fidelity Series Total Market Index Fund1,5980.01%US$1,406No changeMay 31, 2026

Big stakes

HolderStakeSharesDate
C/M Capital Partners, LP9.99%1.6MAug 16, 2026
Jenkins Casey A.9.90%832KDec 31, 2024
SEG JETS SPV I, LLC9.79%1.07MJul 20, 2026
Gregory Castaldo7.50%177KFeb 6, 2026
Joseph Reda7.50%177KFeb 6, 2026
Anson Funds Management LP6.00%1.26MSep 30, 2026
JENKINS DAVID A2.10%194KJan 29, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Andrew Arno
Other companies: 22nd Century Group, Inc (Director · Since at least Jul 19, 2023); Insight Molecular Diagnostics Inc. (Director · Since at least Dec 30, 2015); Smith Micro Software, Inc. (Director · Since at least Jul 27, 2011); Asterias Biotherapeutics Inc (Director · Jun 25, 2015 – Jun 21, 2018 · Past)
Director · Since at least Jul 3, 2024
Philip J Anderson
Other companies: Crown ElectroKinetics Corp. (Chief Financial Officer · Jan 28, 2021 – Jan 28, 2021 · Past); Edison Nation Inc (Chief Financial Officer · May 8, 2018 – May 8, 2018 · Past); Xspand Products Lab Inc (Chief Financial Officer · Apr 4, 2018 – Apr 4, 2018 · Past); COPsync Inc (Chief Financial Officer · Jan 2, 2017 – Jan 2, 2017 · Past)
Chief Financial Officer · Since at least Jan 6, 2025
David Jenkins
Other companies: Intelligent Bio Solutions Inc. (Director · Oct 4, 2022 – Oct 4, 2022 · Past)
Chairman of the Board and CEO, Director · Since at least Jan 16, 2024
James Joseph Caruso
Other companies: Ep Medsystems Inc (VP & Chief Financial Officer · Apr 17, 2007 – Apr 17, 2007 · Past)
Director · Since at least Jan 8, 2024
Martin J Colombatto
Other companies: PLX Technology Inc (Director · Dec 19, 2013 – Aug 12, 2014 · Past)
Director · Since at least Jan 8, 2024
John P FrancisDirector · Jan 2, 2024 – Jan 8, 2024 · Past
Margrit ThomassenInterim CFO and Secretary · Jan 2, 2024 – Jan 8, 2024 · Past
Marie-Claude JacquesChief Commercial Officer · May 1, 2024 – Jan 29, 2025 · Past
Phil AndersonChief Financial Officer · Since at least Apr 23, 2025

Open People

Log in to ask 6ix AI your own questions about Catheter Precision, Inc.